On the fly News and insights, exclusive to thefly.com

AKTX

Akari Therapeutics

$4.90

-0.14 (-2.78%)

, UTSI

UTStarcom

$5.25

0.04 (0.77%)

17:20
12/08/17
12/08
17:20
12/08/17
17:20

On The Fly: After Hours Movers

HIGHER: Akari Therapeutics (AKTX), up 14.3% after it said that its Coversin Phase II trial met its primary endpoint... UTStarcom (UTSI), up 7.6% after the Tonghao Group reported a 9.9% stake in the company... Fate Therapeutics (FATE), up 6.7% after it treated its first patient in the APOLLO study of Fate-NK100... Overstock.com (OSTK), up 3.8% after Morgan Stanley (MS) reported an 11.4% passive stake in the company. LOWER: Cytokinetics (CYTK), down 5% after it said its VITALITY-ALS trial did not meet its primary endpoint.

AKTX

Akari Therapeutics

$4.90

-0.14 (-2.78%)

UTSI

UTStarcom

$5.25

0.04 (0.77%)

FATE

Fate Therapeutics

$4.17

-0.02 (-0.48%)

OSTK

Overstock.com

$45.08

-0.575 (-1.26%)

MS

Morgan Stanley

$52.89

0.54 (1.03%)

CYTK

Cytokinetics

$8.00

-0.1 (-1.23%)

  • 09

    Dec

  • 10

    Dec

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.